MOUNTAIN VIEW, Calif., Feb. 13, 2013 (GLOBE NEWSWIRE) -- Bavarian Nordic ImmunoTherapeutics, a division of Bavarian Nordic (OMX:BAVA) today announced that four abstracts on the Company's therapeutic cancer vaccine candidates for the treatment of prostate cancer, PROSTVAC(R) and MVA-BN(R) PRO will be the subject of four clinical presentations at the 2013 Genitourinary Cancers Symposium on February 14-16, 2013 in Orlando, Florida.
- Abstract #57: Effect of PSA-TRICOM, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in non-metastatic PCa. Presenter: James L. Gulley, M.D., Ph.D., F.A.C.P.-Laboratory of Tumor Immunology and Biology, Medical Oncology Branch, National Cancer Institute (NCI) In this NCI sponsored study, the effect of PSA-TRICOM (PROSTVAC(R)) vaccination was evaluated in 50 hormone naive patients with non-metastatic prostate cancer in a multi-center trial (ECOG 9802). Prostate specific antigen (PSA) values were used to calculate tumor growth rate within the first 100 days of treatment. The preliminary data from this study suggest that PROSTVAC(R) can alter the tumor growth rate significantly within 3 months after therapy initiation. The slowing of tumor growth rate could potentially translate to an improved overall survival, which will be evaluated in the ongoing global PROSPECT Phase 3 trial of PROSTVAC(R), in asymptomatic or minimally symptomatic, metastatic castration-resistant prostate cancer that is currently enrolling patients.
- Abstract # 102: A Phase II randomized clinical trial of Samarium-153 EDTMP (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel. Presenter: Christopher Ryan Heery, MD - Laboratory of Tumor Immunology and Biology, Medical Oncology Branch, National Cancer Institute This NCI-sponsored Phase 2 multi-center trial was designed to evaluate the progression-free survival (PFS) in metastatic castration-resistant prostate cancer patients receiving either Sm-153 alone (Arm A) or in combination with PROSTVAC(R) (Arm B). Of 44 patients enrolled, 39 were evaluable. At four months, the PFS for evaluable patients in Arm A was 11.1% (2/18 patients) compared to 23.8% (5/21 patients) in Arm B. Median PFS for patients in Arm A was 1.7 months compared to 3.7 months in Arm B. (Hazard ratio 0.502, p=0.045) This final analysis suggests the combination of PROSTVAC(R) and Sm-153 has a similar toxicity profile to Sm-153 alone. Also, it appears to demonstrate improvement in PFS with the combination. This may indicate potential synergy between PROSTVAC(R) and bone-seeking radiopharmaceuticals.
- Abstract #85: Safety profile of poxviral vaccines: NCI experience Presenter: Joseph W. Kim, MD - Laboratory of Tumor Immunology and Biology, Medical Oncology Branch, National Cancer Institute This abstract evaluates data from a total of 1,343 subcutaneous poxviral injections from 215 patients in 8 NCI-sponsored clinical trials. Each vaccine consisted of recombinant vaccinia and recombinant fowlpox encoded with 3 human costimulatory molecules (TRICOM), and prostate specific antigen (PSA) - PROSTVAC(R), or carcinoembryonic antigen (CEA) and mucin-1 (MUC-1) which is CV-301 (CEA-MUC-1-TRICOM). No contact transmissions, inadvertent inoculations, or any serious adverse events related to vaccinia were observed in these eight studies. Grade 2 injection site reactions were reported in 31% (423 poxviral injections). These preliminary data suggest that poxviral vaccines are well-tolerated at a broad range of doses, in combination with other treatments, and in various tumor types.
- Abstract #193: Phase I dose escalation trial of MVA-BN(R) PRO in men with non-metastatic castration-resistant prostate cancer. Presenter: David G. McLeod, MD - Walter Reed National Military Medical Center In this open label Phase 1 dose escalation multi-center trial, MVA-BN(R) PRO, an investigational prostate cancer immunotherapy designed to express sequences that control immunity to prostate specific antigen (PSA) and Prostatic Acid Phosphatase (PAP), was administered to twenty-four subjects with non-metastatic castration-resistant prostate cancer. All subjects completed the initial 3 vaccinations (treatment) and 21 subjects received 6 vaccinations (re-treatment). Seven responders received additional vaccinations during the extended treatment. MVA-BN(R) PRO was well-tolerated across all dose regimens and no dose-limiting toxicities or severe adverse events were reported. The preliminary study results indicate MVA-BN(R) PRO may have the ability to induce a tumor-specific immune response that may play a role in reducing disease progression.